

# SOMALIA TURKİYE MEDICAL JOURNAL (STMEDJ)

ISSN: 2958-2849





info@stmedj.com

www.stmedj.com



Somalia Turkiye Medical Journal (STMJ) V. 02, No. 04, 2023 doi: 10.58322/stmj.v2i4.33 http://www.stmedj.com ISSN 2958-2849

**Research Article** 

#### Predictive Factors for Detection of Clinically Significant Cancer in Repeat Prostate Biopsy

Uğur Öztürk, Mustafa Aydın, Lokman İrkılata, Muhammet Şahin, Mustafa Kemal Atilla Department of Urology, Samsun University Research and Training Hospital, Samsun, Türkiye

| <b>Corresponding Author</b> | Uğur Öztürk                       | Email: dru.ozturk@gmail.com |
|-----------------------------|-----------------------------------|-----------------------------|
| Received                    | September 11 <sup>th</sup> , 2023 |                             |
| Accepted                    | October 10 <sup>th</sup> , 2023   |                             |

Abstract Introduction: This study aims to identify predictive factors for detecting clinically significant cancer in the second biopsy among patients who underwent two prostate biopsies. Materials and Methods: Between 2016 and 2022, our clinic conducted prostate biopsies in response to elevated prostate-specific antigen (PSA) levels. When the initial pathology did not reveal cancer, patients who subsequently underwent a second biopsy due to the detection of atypical small acinar proliferation (ASAP) and persistent PSA elevation were included in this study. Data from 103 patients were retrospectively evaluated. The initial biopsy followed a 12-quadrant routine protocol. The second biopsy was performed within three months for ASAP cases and six months later for cases with persistent PSA elevation. Pathological staging utilized the Gleason scoring system, with scores of 7 and above indicating clinically significant cancer. Patients were stratified by age (under 65 and 65 and over), and whether their PSA values six months post-initial biopsy exceeded 20%. Statistical analysis employed Fisher's exact test, with a significance threshold set at p<0.05. Results: Of the 103 patients included in the study, cancer was detected in 13 (12.6%) during the second biopsy. Among these, 5 (4.8%) exhibited clinically insignificant cancers meeting active surveillance criteria, while 8 (7.8%) demonstrated a Gleason score of 7 or higher. No significant difference in cancer detection or identification of clinically significant cancer was observed between patients with ASAP at the first biopsy and those without (p=0.982). However, the rate of clinically significant cancer was notably higher at 15.4% in patients with a PSA increase of over 20%, compared to 3.1% in those without an increase (p=0.024). Furthermore, clinically significant cancer was identified in 14.2% of patients aged 65 and over, as opposed to 1.9% in those under 65 (p=0.019). Conclusions: This study highlights a higher detection rate of clinically significant cancer in patients with a PSA value increase of more than 20% compared to their initial PSA, as well as in individuals aged 65 and over, among those who underwent a prostate biopsy due to elevated PSA levels initially deemed benign. Timely consideration of a second biopsy is crucial for these patient cohorts.

Keywords Prostate; biopsy; ASAP; cancer

#### Introduction

Prostate cancer (PCa) stands as the second most prevalent malignancy in men and ranks as the fifth leading cause of global mortality. Elevated plasmatic levels of prostate-specific antigen (PSA> 4 ng/mL), a glycoprotein predominantly expressed by prostate tissue, serve as the basis for detecting many cases of prostate cancer. However, given that non-cancerous

individuals may also exhibit elevated PSA levels, tissue biopsy remains the gold standard for confirming the presence of cancer (1). Prostate biopsy outcomes encompass a spectrum of findings, ranging from PCa to benign prostatic hyperplasia (BPH), high-grade prostate intraepithelial neoplasia (HGPIN), and atypical small acinar proliferation (ASAP) (2). This study seeks to elucidate the predictive factors for identifying clinically significant cancer in the second biopsy among cases where the initial biopsy yielded no evidence of prostate cancer.

#### **Materials and Methods**

Between 2016 and 2022, our clinic conducted prostate biopsies in response to elevated prostatespecific antigen (PSA) levels. In cases where no cancer was detected in the initial pathology, patients who subsequently underwent a second biopsy due to the detection of atypical small acinar proliferation (ASAP) and the persistence of elevated PSA were enrolled in this

study. The data of 103 patients were retrospectively accessed and evaluated. The initial biopsy adhered to a 12-quadrant routine protocol. This procedure was performed with the patient in the lateral decubitus position, employing standard grayscale ultrasonography and a 7.5 MHz rectal probe (Mindray M5, Shenzhen, China). A biopsy needle of 18 Gauge and an automatic biopsy gun (GEOTEK Estacore, Daventry, UK) were utilized.

For patients with ASAP, the second biopsy was conducted within three months, while those with persistent PSA elevation underwent the procedure six months after the initial biopsy. Pathological

staging utilized the Gleason scoring system, with a Gleason score of 7 or higher indicating clinically significant cancer. Additionally, patients were categorized by age, distinguishing those under 65 from those who were not.

#### Statistical Analysis

The statistical analysis employed the Statistical Package for the Social Sciences version 22 (SPSS Inc, Chicago, USA). The normal distribution of the data was assessed using the Shapiro-Wilk test. Fisher's exact test was employed for statistical comparisons. A p value below 0.05 was considered statistically significant in the analysis.

## Results

A total of 103 patients were included in the study. Cancer was detected in 13 (12.6%) patients during the second biopsy. Among these cases, 5 (4.8%) were classified as clinically insignificant cancers, meeting the criteria for active surveillance, while 8 (7.8%) exhibited a Gleason score of 7 or higher.

No significant difference was observed in the detection of cancer or clinically significant cancer during the second biopsy between individuals with or without ASAP in the initial biopsy (p =0.982).

In cases where there was a PSA increase of more than 20%, the rate of clinically significant cancer stood at 15.4%, whereas it was notably lower at 3.1% in those without such an increase (p=0.024). Furthermore, the prevalence of clinically significant cancer was notably higher at 14.2% in individuals aged 65 and over, in contrast to a lower rate of 1.9% in those younger than 65 (p=0.019) (Table 1).

|                                  | Benign     | Clinically insignificant cancer | Clinically significant cancer | p value |
|----------------------------------|------------|---------------------------------|-------------------------------|---------|
| Number of patients (103)         | 90 (87,4%) | 5 (4,8%)                        | 8 (7,8%)                      |         |
| First biopsy result:<br>ASAP (+) | 34 (87,2%) | 2 (5,1%)                        | 3(7,7%)                       | 0,982   |
| First biopsy result<br>ASAP (-)  | 56 (87,5%) | 3(4,7%)                         | 5 (7,8%)                      |         |
| PSA increase>20%<br>(+)          | 32 (82%)   | 1 (2,6%)                        | 6 (15,4%)                     | 0,024*  |
| PSA increase>20% (-<br>)         | 58(90,7%)  | 4 (6,2%)                        | 2 (3,1%)                      |         |
| Age≥65                           | 42 (85,8)  | 0                               | 7 (14,2%)                     | 0,019*  |
| Age<65                           | 48 (%88,9) | 5(9,2)                          | 1 (1,9%)                      |         |

# Table 1. Comparison of the cases according to the pathology results and other parameters

\*p-value is significant below 0.05

#### Discussion

Prostate-specific antigen (PSA) remains the cornerstone of screening studies for prostate cancer. Elevated PSA levels above 4.0 ng/ml serve as an indication for prostate biopsy, with an escalating probability of adenocarcinoma as PSA values rise (4). Additionally, reports indicate that prostate cancer is detected in 5-20% of biopsies performed for various indications in patients with PSA values at or below 4.0 ng/ml (5).

In cases where the initial biopsy yields no evidence of prostate cancer, a re-biopsy may be warranted. European urology guidelines recommend re-biopsy in instances of elevated and high PSA levels, suspicious findings on rectal examination, the presence of atypical small acinar proliferation (ASAP), detection of high-grade prostate intraepithelial neoplasia (HGPIN) in multiple quadrants, and findings on multiparametric MRI (3).

ASAP is encountered in roughly 5% of prostate biopsies, and approximately 30-40% of patients with ASAP demonstrate biopsy-detectable prostate cancer within five years (9). Current guidelines advise a repeat biopsy within 3-6 months following the initial ASAP diagnosis due to the high likelihood of cancer detection on repeat biopsy (7, 8). In alignment with this, our study also implemented a second biopsy within three months for patients with ASAP identified in the first biopsy. The probability of encountering a Gleason score exceeding 6, indicative of high-grade cancer, on repeat biopsy following an ASAP diagnosis, exhibits significant variation across studies, ranging from 8.0% to 66.7% (6).

PSA velocity (PSAV), which reflects changes in PSA levels over time has been proposed to augment prostate cancer detection. It is posited that a rapidly increasing PSA may signal an elevated risk for a prostate cancer diagnosis, even in cases where PSA levels are within the conventional biopsy threshold. Consequently, current National Comprehensive Cancer Network (NCCN) guidelines suggest that men with PSAV $\geq$ 0.35 ng/ml per year should contemplate biopsy, even if their PSA levels fall below the usual biopsy threshold (10). The American Cancer Society advances a similar recommendation for PSAV  $\geq$ 0.75 ng/ml per year and PSA levels between 4-10 ng/ml (11). The European Association of Urology (EAU) advocates for biopsy when PSAV exceeds 0.60 ng/ml per year (12). In our study, we re-measured PSA six months

after the initial biopsy. Those exhibiting a 20% increase above the initial value demonstrated a heightened detection rate of clinically significant prostate cancer.

Prostate cancer is infrequently diagnosed in younger men (under 50), comprising only 2% of all cases. The mean age at diagnosis is 68, with 85% of diagnoses occurring in individuals over 65. Autopsy series reveal microscopic disease rates of 30% in the fourth decade, 50% in the sixth decade, and 75% in individuals over 85 (10). In our study, the clinically significant cancer

detection rate was notably elevated among individuals aged 65 and over, aligning with broader epidemiological trends.

It is worth noting that the absence of a Multiparametric MR imaging system at our institution during the study period represents a limiting factor in our research.

## Conclusion

While prostate biopsy stands as a safe and effective diagnostic procedure, it is imperative to acknowledge the associated risks of complications and financial considerations. Furthermore, the notion of repeat biopsy may induce anxiety in patients. Therefore, a judicious patient selection process is crucial in order to enhance the likelihood of a positive biopsy outcome and diminish the necessity for unnecessary procedures. Predictive factors play a pivotal role in this regard. Specifically, among patients who underwent prostate biopsy due to elevated PSA levels initially deemed benign, those demonstrating a follow-up PSA measurement exceeding 20% compared to the initial PSA, coupled with an age surpassing 65, exhibited significant predictive value. These findings constitute noteworthy contributions to our study.

# **Conflict of Interest**

The authors disclose no potential conflicts of interest about this study.

# **Ethical Approval**

Approval from the Clinical Research Ethics Committee of Samsun University was obtained under protocol number SÜKAEK-2022/4/7.

# Funding

This study did not receive any external funding.

# References

1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019;10(2):63-89.

- 2. Kim TS, Ko KJ, Shin SJ, et al. Multiple cores of high grade prostatic intraepithelial neoplasia and any core of atypia on first biopsy are significant predictor for cancer detection at a repeat biopsy. *Korean J Urol* 2015;56(12):796-802.
- 3. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol* 2017;71(4):618-629.
- 4. Cooner WH, Mosley BR, Rutherford CL, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. *J Urol* 1990; 143(8):1146-1152.
- 5. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. *N Engl J Med* 1991;324(9):1156-1161.
- 6. Imanaka T, Yoshida T, Taniguchi A, et al. Implementation of repeat biopsy and detection of cancer after a diagnosis of atypical small acinar proliferation of the prostate. *Mol Clin Oncol* 2020;13(6):67.
- Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 2014;12(9):1211-1219.
- 8. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. *Eur Urol* 2014;65:124–137.
- 9. Kim H, Kim JK, Choe G, et al. Clinical strategy of repeat biopsy in patients with atypical small acinar proliferation (ASAP). *Sci Rep* 2021;11(1):23143.
- 10. Bell KJ, Del Mar C, Wright G, et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. *Int J Cancer* 2015;137(7):1749-1757.
- 11. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320–1328.
- 12. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. *J Natl Cancer Inst* 2006; 98:1128–1133.
- 13. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. *Eur Urol* 2008;53:68–80.



(1777)

**Research Article** 

# Pulmonary Physiotherapy in Kidney Recipients: Evaluation of Effects on Functional Capacity and Quality of Life

Zuhal Zeydan<sup>1</sup>, Makbule Ergin<sup>2</sup>

(DDT) ' 1 1' 1' 1 1' 11'1

<sup>1</sup>Department of Physiotherapy, Antalya Medical Park Hospital, Antalya Turkiye.

<sup>2</sup>Department of Chest Surgery, Akdeniz University Hospital, Antalya Turkiye.

| <b>Corresponding Author</b> | Zuhal Zeydan                      | Email: zuhalzeydan@gmail.com |
|-----------------------------|-----------------------------------|------------------------------|
| Received                    | September 15 <sup>th</sup> , 2023 |                              |
| Accepted                    | October 10 <sup>th</sup> , 2023   |                              |

. .1

| Abstract | introduction: Kenal replacement inerapy (KK1), including dialysis and kidney transplantation (K1), is employed       |
|----------|--|
|          | for treating patients with end-stage renal disease (ESRD). Among RRT options, KT offers the highest quality of       |
|          | life (QoL) and overall survival. However, pulmonary complications following KT remain significant contributors       |
|          | to morbidity, mortality, and potential graft failure. The primary objective of this study is to assess the impact of |
|          | respiratory and strengthening exercises on respiration, body composition, physical performance, and QoL of the       |
|          | patients following KT. Materials and Methods: Preoperative assessments included forced expiratory volume in          |
|          | one second (FEV1), 6-minute walking test (6MWT) scores, body composition measurements, hand grip strength,           |
|          | and QoL scores using the Short Form 36 Scale (SF-36) for the patients undergoing their first KT at Antalya           |
|          | Medical Park Hospital. Participants were randomly assigned to two groups. The experimental group (EG) received       |
|          | respiratory exercises until discharge, followed by combined respiratory, upper, and lower extremity strengthening    |
|          | exercises three days a week for two weeks post-discharge, while the control group (CG) received standard care.       |
|          | Measurements were repeated at the end of the third postoperative week, and the changes from the initial              |
|          | measurements were statistically compared between the groups. Results: Demographic characteristics were               |
|          | comparable between the groups. The SF-36 physical function sub-parameter demonstrated a significant increase         |
|          | in the experimental group, while it decreased in the control group. Pain sub-parameter scores and grip strengths     |
|          | of the SF-36 QoL scale did not exhibit statistically significant changes in either group. Conclusion: Implementing   |
|          | early respiratory physiotherapy and strengthening program over three weeks following KT improved QoL and             |
|          | physical function significantly.   |
|          |  |

Keywords pulmonary physiotherapy; postoperative exercise; kidney transplantation

#### Introduction

Chronic kidney disease (CKD) is a persistent clinical condition characterized by the progressive deterioration of renal function (1). It was suggested that CKD would rank as the fifth leading global cause of mortality in 2040 (2).

As per another definition, when the glomerular filtration rate (GFR) falls below 15 ml/min, it signifies end-stage disease (ESRD). In this critical phase, patients undergo renal replacement therapies, encompassing peritoneal dialysis, hemodialysis, and kidney transplantation (KT) (3). Among these options, KT provides the highest success rate and survival outcome. While successful KT leads to improved quality of life (QoL) and reduced mortality risk, specific functional indicators such as QoL, muscle strength, and physical activity tend to be notably lower in KT recipients compared to their healthy counterparts (1,4).

It is known that pulmonary complications constitute a significant source of morbidity and mortality after KT (5). Ucan et al. reported that in solid organ transplantations, hospital-acquired infections are most prevalent within the first month, and the post-KT 6-month period was associated with the highest intensity of immunosuppression, resulting in a higher incidence of opportunistic infections such as cytomegalovirus (CMV), aspergillus, and others (6).

Beyond the sixth month, due to ongoing maintenance immunosuppression, community-acquired infectious agents and opportunistic pathogens such as S. pneumonia, H. influenza, Nocardia, and M. tuberculosis may cause infections in these patients. In line with this suggestion, Zeyneloğlu noted that early-stage respiratory failure was most commonly due to cardiogenic pulmonary edema, while bacterial pneumonia was the underlying cause more commonly in the subsequent months or years after KT (7).

Pencheva et al. followed 267 KT recipients for seven years post-transplant to monitor the development of pulmonary complications and their outcomes (5). These authors reported that 97 recipients experienced pulmonary complications, leading to 31 mortalities. Consequently, they highlighted the risk for mortality and graft failure due to post-KT pulmonary complications.

Fishman stated that immunosuppressive therapy significantly reduced the incidence of graft rejections but increased the susceptibility to opportunistic infections and cancer (8).

Pulmonary rehabilitation (PR) constitutes a tailored, multidisciplinary care program to address the specific therapeutic needs arising from chronic respiratory conditions (9,10). The primary objective of PR is to sustain the patient's daily activities and quality of life at an optimal level. It was shown that inpatient or outpatient PR programs substantially improved the clinical status and functional capacity. Since there is typically a reduction in functional residual and vital capacity following thoracic and abdominal surgeries, postoperative emphasis on respiratory exercises and cough training becomes crucial. Additionally, in conditions affecting the respiratory system, increased exercise capacity can be achieved through enhanced functionality of skeletal muscles involved in physical activities, allowing patients to perform daily tasks with reduced respiratory effort (11). Notably, it was reported that heightened physical activity positively correlated with graft function within the first year after KT (12).

The objective of this study was to assess the impact of respiratory exercises initiated from the first postoperative day, coupled with post-discharge upper and lower extremity strengthening exercises, on FEV1 values, 6-minute walking test (6MWT) results, body composition, QoL, and grip strength in KT recipients.

## Materials and Methods

#### Study Design

This study was designed as a prospective randomized controlled clinical trial. Patients admitted to Antalya Medical Park Hospital Kidney Transplantation Unit between December 2020 and August 2021 constituted its target population. The study received approval from the Akdeniz University Clinical Research Ethics Committee (KAEK-279/ 08.04.2020). All patients and study participants gave written and verbal consent before enrollment.

#### Assessments

#### Personal Data Form

A personal data form including demographic characteristics, education level, body mass index (BMI), Coronavirus disease-2019 (COVID-19) history, alcohol use, smoking habits, history of dialysis, and the primary reason for ESRD was filled out for each study participant.

#### 6-Minute Walk Test

During the 6MWT, participants were instructed to walk the maximum distance they could in six minutes along a 30-meter corridor marked every three meters. They were informed they could rest if needed, but the timer would continue. Oxygen saturation, blood pressure, and heart rate were monitored before and after the test, and the distance walked was recorded in meters.

#### Respiratory function test

A spirometry device (ZAN300 CO Diffusion®, Spire Health, USA) with ZAN GPI 3.xx software was used. Data including height, weight, age, and gender were recorded in the spirometry program. Patients were instructed to breathe normally three times while wearing a nose clip. Subsequently, they were instructed to take the deepest breath possible and exhale forcefully at maximum speed. The highest FEV1 value among the three acceptable tests was recorded.

## Assessment of body composition

This assessment was performed using an MC-980 Body Composition Analyzer (Tanita Corp. Tokyo- Japan) measuring device. Before measurement, patients were asked to remove their socks, weight-bearing clothes, and any metal accessories. Height, gender, age, and date of birth were recorded on the device. The measurements included fat tissue percentage, BMI, lean tissue percentage, body weight, body fat weight, body water content, and lean tissue weight. The calculations were recorded as percentages or kilograms.

#### Upper extremity muscle strength measurements

Grip strength was assessed in kilograms using a Smedley hand dynamometer. Participants were instructed to squeeze and relax the dynamometer with their right and left hands with maximum force, respectively. These maneuvers were performed while the patient was sitting upright on a back-supported chair with the shoulder in adduction adjacent to the trunk, the elbow in 90 degrees flexion, and the wrist in 0-30 degrees extension. The test was repeated three times, and the researcher recorded the mean value in kilograms/force.

#### Measurement of the serum urea and creatinine levels

Serum urea and creatinine values measured in the last week before KT and three weeks after KT were recorded as initial and final values.

#### QoL assessment

The Short Form 36 Scale, which encompasses 36 questions, assesses various facets of general health and physical well-being over the preceding four weeks. These include physical functioning, role limitations due to physical issues, physical pain, overall physical health, vitality, social functioning, role limitations due to emotional issues, and general mental health. Each category is scored on a scale from 0 to 100 points. Lower scores indicate a lower QoL, while higher scores

are associated with a higher QoL. While the total score can be used, each category can be evaluated separately.

In our study, one of the researchers asked the participants all SF-36 questions in a room at the KT outpatient clinic. The responses were recorded, and scores for each subcategory were noted.

# Exercise protocol

After recording their preoperative assessment results, all patients were instructed on using the spirometer and the significance of postoperative breathing and coughing. They were advised to perform spirometry exercises 10 times every 1-2 hours during the daytime during the first-week post-KT and 10 times at least 3 times daily in the second and third weeks.

# Study protocol for the experimental group

In addition to the spirometry, patients in the experimental group practiced apical, basal, and diaphragmatic breathing exercises with puckered lip breathing twice daily (i.e., 10x2) for three weeks post-KT. They performed 9 upper and lower extremity strengthening exercises 3 times a week (10 exercises each time) starting from post-KT day 5-7 until the end of the third post-KT week. These exercises were conducted under the supervision of a researcher in an exercise room at the KT outpatient clinic. The intensity of the exercises was gradually increased based on the patient's clinical condition, and by the end of the third week, strengthening exercises were performed with three sets of 15 repetitions.

# Statistical analysis

Statistical analyses were conducted using Statistical Package for Social Sciences (SPSS Statistics for Windows, v24, IBM Corp., Armonk, NY, USA). The normal distribution of variables was assessed using visual (histograms and probability plots) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk). Descriptive analyses were presented using mean and standard deviation

for normally distributed variables, while nominal variables were expressed as counts and percentages. The Student's t test was employed to ascertain the significance of differences between the means of the experimental and control groups. The Chi-square test (Pearson chi-square) was utilized to analyze the relationship between categorical variables. Mixed design repeated measures two-way analysis of variance (i.e., mixed design repeated measures ANOVA) was employed to assess changes in the variables of the experimental and control groups over time, as well as group-time interactions. The total type-1 error level for statistical significance was set at 5%.

## Results

Overall, 53 patients were included. The experimental group included 27 patients, while there were 26 patients in the control group (Table 1). The control and the experimental groups had a mean age of  $41.2\pm14.1$  and  $35.3\pm11.1$  years, respectively. The ratios of female patients were 34.6% (n=9) and 40.7% (n=11) in the control and experimental groups.

|                         |                    | Control Group |      | Experim    | ental Group |          |       |
|-------------------------|--------------------|---------------|------|------------|-------------|----------|-------|
|                         |                    | (n=26)        |      | ( <b>r</b> | n=27)       | 4        | -     |
|                         |                    | X             | SD   | Х          | SD          | ι        | h     |
| Age (years)             |                    | 41,2          | 14,1 | 35,3       | 11,1        | 1,68     | 0,098 |
| Height (cm)             |                    | 167,3         | 8,0  | 164,4      | 10,2        | 1,15     | 0,254 |
| Daily smoked cig        | garette (pack/day) | 1,9           | 4,9  | 3,7        | 9,3         | -0,86    | 0,389 |
| Smoking period (Months) |                    | 108,0         | 78,7 | 208,8      | 145,1       | -1,08    | 0,319 |
|                         |                    | n             | (%)  | n          | (%)         | $\chi^2$ | р     |
| Gender                  | Female             | 9             | 34,6 | 11         | 40,7        | 0.21     | 0.646 |
|                         | Male               | 17            | 65,4 | 16         | 59,3        | 0,21     | 0,646 |
| Education Level         | Primary Education  | 9             | 34,6 | 12         | 44,4        |          |       |
|                         | High School        | 8             | 30,8 | 7          | 25,9        | 0,53     | 0,765 |
|                         | Bachelor and above | 9             | 34,6 | 8          | 29,6        |          |       |
| Alcohol Use             | Yes                | 0             | 0,0  | 0          | 0,0         |          |       |
|                         | No                 | 26            | 100  | 27         | 100         |          |       |

Table 1. Comparative analysis of sociodemographic characteristics between the groups

| Smoking | Yes | 4  | 15,4 | 5  | 18,5 | 0.09 | 0 761 |
|---------|-----|----|------|----|------|------|-------|
|         | No  | 22 | 84,6 | 22 | 81,5 | 0,05 | 0,701 |

t: Student's T test, X<sup>2</sup>: Chi-square test, M: mean, SD: Standard deviation

There were no statistically significant differences between the groups regarding gender distribution, educational level, smoking, and alcohol use (p>0.05). Similarly, the two groups did not significantly differ concerning the primary reason for ESRD (Table 2). In the control group, 30.8% had hypertension (HT), 7.7% had diabetes mellitus (DM), 19.2% had nephrological or urological diseases, 3.8% had genetic causes leading to ESRD, while 38.5% of these patients had other reasons. In the experimental group, 33.3% had HT, 3.7% had DM, 22.2% had nephrological-urological diseases, 18.5% had genetic causes, and 18.5% had other factors causing ESRD.

|                                   |                                       | Control C | Control Group |      | ental Group |      |       |
|-----------------------------------|---------------------------------------|-----------|---------------|------|-------------|------|-------|
|                                   |                                       | (n=2      | (n=26)        |      | (n=27)      |      | n     |
|                                   |                                       | n         | (%)           | n    | (%)         | χ    | Р     |
| Hypertension<br>Diabetes mellitus | 8                                     | 30,8      | 9             | 33,3 |             |      |       |
|                                   | Diabetes mellitus                     | 2         | 7,7           | 1    | 3,7         |      |       |
| etiology                          | Nephrological-<br>Urological Diseases | 5         | 19,2          | 6    | 22,2        | 4,13 | 0,388 |
|                                   | Genetic Causes                        | 1         | 3,8           | 5    | 18,5        |      |       |
|                                   | Other Causes                          | 10        | 38,5          | 6    | 22,2        |      |       |

Table 2. Classification of Experimental and Control Groups according to ESRD etiology

 $\chi^2$ : Chi-square tets, X: mean, SD: Standard deviation, ESRD: End Stage Renal Disease

In both groups, the comparison between initial and final measurements of weight and BMI showed statistically significant differences (p<0.05) (Table 3).

Table 3. Comparison of the first and last measurements of weight and BMI between the groups

| Control<br>(n= | Group<br>=26) | Experi<br>Gro<br>(n= | mental<br>oup<br>27) | Time | Group<br>* Time | n <sup>2</sup> |
|----------------|---------------|----------------------|----------------------|------|-----------------|----------------|
| X              | SD            | Х                    | SD                   | F/p  | F/p             |                |

| Body | First<br>Measurement | 70,7 | 15,2 | 67,7 | 17,5 | 20,32 / | 4,02 / | 0.073 |
|------|----------------------|------|------|------|------|---------|--------|-------|
| (kg) | Final<br>Measurement | 67,6 | 13,8 | 66,5 | 16,7 | 0,000   | 0,048  | 0,075 |
| BMI  | First<br>Measurement | 25,2 | 4,6  | 25,2 | 7,3  | 19,28 / | 3,44 / | 0,063 |
|      | Final<br>Measurement | 24,1 | 4,3  | 24,7 | 7,0  | 0,000   | 0,069  |       |

Two-way Analysis of Variance in Repeated Measurements, n2: Effect size, \*\*p<0.01, \*p<0.05, BMI: Body-mass index, X: mean, SD: Standard deviation

Although the mean patient weight significantly decreased in both groups, the difference was significantly higher in the control group (p < 0.05).

In addition, both groups experienced a statistically significant reduction in muscle mass (p<0.05) (Table 4). However, the comparison of the muscle mass reduction between the two groups did not reveal a statistically significant difference (p>0.05). There was no statistically significant difference in the initial and final measurement values of fat mass in both groups, and the change in fat mass over time was also similar (p>0.05).

| groups    |                      |                         |     |                 |                    |                      |                |                |
|-----------|----------------------|-------------------------|-----|-----------------|--------------------|----------------------|----------------|----------------|
|           |                      | Control Group<br>(n=26) |     | Experime<br>(n= | ntal Group<br>=27) | Time                 | Group<br>*Time | n <sup>2</sup> |
|           |                      | X                       | SD  | X               | SD                 | F/p                  | F/p            |                |
| Muscle    | First<br>measurement | 52,9                    | 9,2 | 50,5            | 10,1               | 21,99 / <b>0,000</b> | 3,58 /         | 0.066          |
| mass (kg) | Final                | 49,8                    | 7,8 | 49,2            | 9,6                |                      | 0,064          | 0,000          |

16,0

14,4

13,7

10,7

Table 4. Comparison of the muscle mass and fat mass values of the experimental and control

| Two-way Analysis of Variance in Repeated Measurements, | n2: Effect size, | **p<0.01, | *p<0.05, | X: mean, | SD. |
|--|------------------|-----------|----------|----------|-----|
| Standard deviation                                     |                  |           |          |          |     |

9,6

9,1

measurement

measurement

measurement

15,0

15,2

First

Final

Fat mass

(kg)

0,77/

0,382

0,015

0,43 / 0,513

Our analysis also revealed that fat-free mass decreased and fat percentage increased in both groups

(Table 5).

|                   |                      | Control Group<br>(n=26) |      | Experimental Group<br>(n=27) |      | Time                 | Group<br>*Time | n <sup>2</sup> |
|-------------------|----------------------|-------------------------|------|------------------------------|------|----------------------|----------------|----------------|
|                   |                      | X                       | SD   | X                            | SD   | F/p                  | F/p            |                |
| Lean mass         | First<br>measurement | 55,7                    | 9,7  | 53,2                         | 10,6 | 22,18 / <b>0,000</b> | 3,63 /         | 0.067          |
| (kg)              | Final<br>measurement | 52,4                    | 8,2  | 51,8                         | 10,1 |                      | 0,062          | 0,007          |
| Fat<br>percentage | First<br>measurement | 19,9                    | 10,3 | 19,6                         | 11,0 | 6,96 / <b>0,011</b>  | 0,30 /         | 0,006          |
| (%)               | Final measurement    | 21,2                    | 9,9  | 20,5                         | 10,2 |                      | 0,581          |                |

**Table 5.** Comparison of the first and last measurements of the fat-free mass and fat percentage between the experimental and control groups

Two-way Analysis of Variance in Repeated Measurements, n2; Effect size, \*\*p<0.01, \*p<0.05, X: mean, SD: Standard deviation

The comparison between initial and final measurements for fat-free mass and fat percentage in both groups showed statistically significant differences (p<0.05). However, no statistical difference was found in the comparison of these variables between the groups (p>0.05).

The FEV1 values increased significantly in both groups (p<0.05) (Table 6).

| Table 6. Comparison of the FEV1 | measurements between the experimental and cont | rol groups |
|---------------------------------|--|------------|
| 1                               | 1  | 0 1        |

|      |                      | Contro<br>(n=2 | l Group<br>26) | Experimental Group<br>(n=27) |      | Time                | Group<br>*Time | n <sup>2</sup> |
|------|----------------------|----------------|----------------|------------------------------|------|---------------------|----------------|----------------|
|      |                      | X              | SD             | X                            | SD   | F/p                 | F/p            |                |
| FEV1 | First<br>measurement | 69,5           | 8,5            | 73,5                         | 12,1 | 47,77/ <b>0,000</b> |                |                |

| Final       |      |      |      |      | 0,21/0,64 | 0,004 |
|-------------|------|------|------|------|-----------|-------|
| measurement | 78,3 | 12,6 | 83,6 | 13,2 | 4         |       |
|             |      |      |      |      |           |       |

Two-way Analysis of Variance in Repeated Measurements, n2; Effect size, \*\*p<0.01, \*p<0.05, FEV1: Forced expiratory volume 1; X: mean, SD: Standard deviation

However, there was no statistically significant difference between the groups regarding the change

in FEV1 (p>0.05).

The 6MWT scores showed a statistically significant increase in both groups (p<0.05). However,

the comparison of the changes between the two groups revealed no significant difference (p>0.05).

Notably, the 6WWT scores were lower than the typical values in healthy individuals in both groups

(Table 7).

**Table 7.** Comparison of the first and last 6-Minute Walk Test (6 MWT) results between the experimental and control groups

|          |                      | Control<br>Group (n=26) |      | Experimental<br>Group<br>(n=27) |      | Time    | Group<br>*Time | n <sup>2</sup> |
|----------|----------------------|-------------------------|------|---------------------------------|------|---------|----------------|----------------|
|          |                      | X                       | SD   | X                               | SD   | F/p     | F/p            |                |
| 6MWT     | First<br>measurement | 413,2                   | 92,0 | 456,0                           | 75,8 | 13,75 / | 0,58 /         | 0.011          |
| (meters) | Final<br>measurement | 444,0                   | 93,3 | 502,9                           | 64,8 | 0,001   | 0,450          | 0,011          |

Two-way Analysis of Variance in Repeated Measurements, n2: Effect size, \*p<0.01, \*p<0.05, 6MWT: 6-minute walk test; X: mea;, SD: Standard deviation.

There was no statistically significant difference in the changes in grip strength in the right and left

hands over time for both groups (p>0.05) (Table 8).

**Table 8.** Comparison of the first and last measurements of the right and left hand grip strengths

 between the groups

| Control<br>Group (n=26) | Experimental<br>Group<br>(n=27) | Time | Group<br>*Time | n <sup>2</sup> |
|-------------------------|---------------------------------|------|----------------|----------------|
|-------------------------|---------------------------------|------|----------------|----------------|

|                              |                      | X    | SD  | X    | SD   | F/p    | F/p    |       |
|------------------------------|----------------------|------|-----|------|------|--------|--------|-------|
| Handgrip<br>strength<br>(kg) | First<br>Measurement | 29,9 | 9,4 | 32,0 | 10,1 | 0,86 / | 1,23 / |       |
| Right hand                   | Final<br>Measurement | 29,8 | 9,7 | 33,3 | 10,1 | 0,358  | 0,272  | 0,024 |
| Handgrip<br>strength<br>(kg) | First<br>Measurement | 26,3 | 9,2 | 28,6 | 10,1 | 0,73 / | 0,51 / | 0,010 |
| Left hand                    | Final<br>Measurement | 26,4 | 9,1 | 29,1 | 9,6  | 0,395  | 0,477  |       |

Two-way Analysis of Variance in Repeated Measurements, n2: Effect size, \*\*p<0.01, \*p<0.05, X: mean; SD: Standard deviation

Additionally, there was no statistically significant difference when comparing these changes over

time between the groups (p>0.05).

The serum urea and creatinine values decreased statistically significantly over time in both groups

(p<0.05) (Table 9). The serum urea and creatinine reduction was statistically similar between the

groups (p>0.05).

|          |                      | Control<br>(n=2 | Control Group<br>(n=26) Experimental<br>Group<br>(n=27) |      | Time | Group<br>*Time           | n <sup>2</sup>          |       |
|----------|----------------------|-----------------|---|------|------|--------------------------|-------------------------|-------|
|          |                      | X               | SD  | X    | SD   | F/p                      | F/p                     |       |
| Urea     | First<br>Measurement | 57,9            | 22,5  | 62,4 | 17,8 | 165,47/<br><b>0,000</b>  | ,47/ 1,96 /<br>00 0,167 | 0,037 |
|          | Final<br>Measurement | 24,1            | 10,1  | 20,3 | 7,7  |                          |                         |       |
| Creatine | First<br>Measurement | 6,6             | 2,9   | 7,8  | 2,8  | 245,14 /<br><b>0,000</b> | 2,78 /<br>0,102         | 0.052 |
|          | Final<br>Measurement | 1,1             | 0,4   | 1,1  | 0,3  |                          |                         | 0,032 |

Table 9. Comparison of the renal function tests between the experimental and control groups

*Two-way Analysis of Variance in Repeated Measurements, n2: Effect size,* \*\*p<0.01*,* \*p<0.05*, X: mean; SD: Standard deviation* 

## Somalia Turkiye Medical Journal (STMJ)

## ISSN: 2958-2849 Volume 02, No 04

Our analysis also showed that the physical functioning scale of SF-36 showed a statistically significant increase in the experimental group, while it decreased in the control group (Table 10).

|                              |                      | Co<br>Group | Control<br>Group (n=26) |      | Experimental<br>Group<br>(n=27) |         | Group<br>*Time | n <sup>2</sup> |
|------------------------------|----------------------|-------------|-------------------------|------|---------------------------------|---------|----------------|----------------|
|                              |                      | Χ           | SD                      | X    | SD                              | F/p     | F/p            |                |
| Physical function            | First<br>Measurement | 73,7        | 17,1                    | 60,0 | 20,6                            | 4,53/   | 7 90/0 007     | 0,134          |
|                              | Final<br>Measurement | 72,0        | 12,4                    | 71,9 | 9,9                             | 0,038   | 7,90/0,007     |                |
| Physical role<br>difficulty  | First<br>Measurement | 12,5        | 27,6                    | 9,3  | 15,7                            | 44,56/  | 0.01/0.90      | 0.000          |
|                              | Final<br>Measurement | 40,4        | 20,1                    | 36,2 | 21,3                            | 0,000   | 0,01/0,90      | 0,000          |
| Emotional role<br>difficulty | First<br>Measurement | 34,6        | 40,5                    | 22,2 | 39,2                            | 63,31/  | 0.31/0.57      | 0.006          |
|                              | Final<br>Measurement | 80,8        | 32,9                    | 75,3 | 32,8                            | 0,000   | 0,5170,57      | 0,000          |
| Energy/Vitality              | First<br>Measurement | 38,1        | 19,5                    | 37,0 | 22,2                            | 148,58/ | 0,21/0,644     | 0.004          |
|                              | Final<br>Measurement | 71,5        | 17,7                    | 73,1 | 13,2                            | 0,000   |                | 0,004          |
| Mental health                | First<br>Measurement | 59,1        | 19,2                    | 60,4 | 19,1                            | 65,98/  | 0.02/0.854     | 0.001          |
|                              | Final<br>Measurement | 80,3        | 16,4                    | 82,7 | 10,5                            | 0,000   | 0,03/0,834     | 0,001          |
| Social functioning           | First<br>Measurement | 51,4        | 21,0                    | 44,0 | 31,8                            | 52,62/  | 0.01/0.802     | 0.000          |
|                              | Final<br>Measurement | 20,7        | 22,9                    | 12,0 | 17,8                            | 0,000   | 0,01/0,892     | 0,000          |
| Pain                         | First<br>Measurement | 56,3        | 26,7                    | 65,5 | 24,5                            | 0,59/   | 0 96/0 259     | 0.017          |
|                              | Final<br>Measurement | 63,5        | 19,7                    | 64,8 | 19,6                            | 0,443   | 0,80/0,338     | 0,017          |
| General health               | First<br>Measurement | 30,6        | 13,3                    | 29,4 | 16,2                            | 340,09/ | 1,15/0,28      | 0.022          |
|                              | Final<br>Measurement | 66,3        | 14,2                    | 69,6 | 14,3                            | 0,000   |                | 0,022          |

| Table 10. Comparison | of the SF-36 qua | ality of life scale scores | between the experiment | ntal and control | groups   |
|----------------------|------------------|----------------------------|------------------------|------------------|----------|
|                      |                  |                            |                        |                  | - Stompo |

Two-way Analysis of Variance in Repeated Measurements, n2: Effect size, \*p<0.01, p<0.05, X: mean; SD: Standard deviation. In the post-KT period, the social functioning scale of SF-36 decreased significantly in both groups.

However, the scores regarding the physical role difficulty, emotional role difficulty, mental health, energy/vitality, and general health domains of SF-36 increased significantly and similarly in both groups. The pain scale of SF-36 did not show a significant change between the groups.

## Discussion

This study showed that early respiratory physiotherapy and strengthening performed for three weeks following KT improved QoL and physical functions significantly. On the other hand, the pain scale scores of the SF-36 QoL scale and grip strength did not change significantly in either group.

Many clinical studies investigated the role of exercise training in slowing the progression of ESRD in its early stages, preparing them for RRT, enhancing graft compliance, and improving patients' QoL after KT (13). However, the number of studies analyzing the impact of exercise programs initiated early after KT is limited. In these studies, failure to achieve expected results from exercise training was generally attributed to incision site pain and the ongoing healing process.

Pulmonary rehabilitation is performed to improve the systemic effects of the disease, optimize patients' functional capacity, and reduce pulmonary symptoms and healthcare costs. In the early postoperative period, the goal is to enhance gas exchange and ventilation, preserve functional lung capacity, and facilitate the drainage of secretions.

Our study aimed to assess the impact of respiratory exercises starting from the first postoperative day and the lower and upper extremity strengthening exercises after discharge on FEV1 values, 6MWT scores, QoL, and grip strength in KT recipients.

The similarity of the groups regarding physical, sociodemographic, and clinical characteristics significantly contributed to the homogeneity of the study sample.

Waked et al. conducted a study on 40 KT patients aged between 40 and 60 (14). These researchers divided the cohort into pilates and control groups. The pilates group received training comprising respiratory, strengthening, balance, and coordination exercises for three weeks, starting from the third postoperative day. The authors assessed the participants' quality of life and pulmonary

function 1 day before, 3 days, and 3 weeks after KT. While there was no significant difference in the FEV1 value on the third postoperative day in both groups, the FEV1 value increased significantly in both groups in the third postoperative week, with the exercise group showing statistical superiority over the control group.

As is common in any abdominal surgery, there is a decline in pulmonary functions due to diaphragmatic inhibition resulting from general anesthesia in KT recipients (15). The lack of a significant change in the FEV1 value detected by Waked et al. on the third day after KT can be explained by the findings of this study (14). In our study, similar to the results of Waked et al., a significant increase was found in the FEV1 value of both groups at the end of the third week after KT.

In a meta-analysis assessing the effects of respiratory exercises on respiratory function, it was demonstrated that respiratory exercises can lead to a significant improvement in maximal respiratory pressure after upper abdominal surgery. Grams et al. suggested that most patients undergoing upper or lower abdominal surgery developed a restrictive lung pattern. Thus, these authors stated that respiratory exercises enhanced the mobility of the diaphragm and improved respiratory muscle synergy (16).

In another study, Wang et al. worked on 9 KT recipients six months after KT (17). They performed an aerobic exercise program utilizing video games for 30 minutes 3 days per week for 8 weeks. As a result, they reported a mean increase of 14 meters in the 6MWT walking distance, which is consistent with our study. Onofre et al. analyzed the 6MWT results of 63 recipients before transplantation and on the day of discharge (15). In this study, all patients performed breathing exercises until the day of discharge. In the experimental group, patients practiced upper extremity and walking exercises, gradually intensifying from postoperative day 1 until discharge. Consequently, the authors noted that an exercise program initiated immediately after KT and continued until discharge did not increase the distance walking distance in the 6MWT. They attributed this finding to decreased muscle strength and the adverse effects of the surgery. Our study showed an increase in 6MWT results in both groups within two weeks, probably because surgery-related pain decreased and exercise capacity improved during this period. In line with our findings, Lima et al. reported that a combined exercise training regimen encompassing both aerobic and strengthening exercises enhanced graft function and aerobic capacity (18).

Painter et al. initiated exercise training one month after KT and reported that exercise alone had a limited impact on body composition by the end of the first year (19). Habedank et al. analyzed the dual-energy X-ray absorptiometry (DEXA) and cardiopulmonary exercise test results of 25 patients after KT (20). These researchers noted a shift in participants' body composition towards adipose tissue. They also found that preoperative lean body weight correlated with fat gain after KT. Sánchez et al. conducted a study involving supervised lower and upper extremity strengthening exercises over 10 weeks with participants who underwent KT within one year (21). They reported no significant change in the diameter and mass of the rectus femoris and vastus lateralis muscles. They referred to the small sample size and the lack of nutritional variables that could impact muscle mass in their analysis while noting the limitations of their study.

Our study aligns with the existing literature in terms of the findings regarding the changes in the body composition of the patients. In our cohort, the reduction in body fat-free mass in both patient groups may suggest a potential decrease in muscular strength following the procedure.

In their meta-analysis, Baker et al. claimed that intensive exercise training in the early post-KT period could not prevent declines in physical function (13). However, they recommended encouraging mobility during this period.

One of the postoperative studies included in this meta-analysis is the work of Onofre et al. (15). This report concluded that an exercise program initiated immediately after KT and continued until discharge did not increase peripheral muscle strength. Oguchi et al. reported that corticosteroid use after KT was a risk factor for muscle wasting (22). Sánchez et al. noted in their study with 16 patients who had previously undergone KT within 1 year that grip strength exhibited a statistically significant increase in the exercise group compared to the control group (21). However, the achieved strength was still lower than expected in a healthy population. In their study, including patients who had previously undergone KT, Lima et al. reported that a combined exercise program comprising both aerobic and strengthening exercises for 12 weeks positively impacted grip strength (18). Notably, these two studies were conducted with participants who had previously undergone KT, and the exercise programs were more prolonged than ours. This finding may account for the significant increase in grip strength observed in kidney transplant recipients in these studies.

Sánchez et al. reported that following 10 weeks of supervised resistance exercise training with 16 patients who had undergone KT within one year, the exercise group had significantly higher physical role and vitality scores than the control group (21). However, it should be noted that the results were lower than anticipated for a healthy population.

Mazzoni et al. compared the data of 118 KT recipients engaged in low and moderate-intensity regular sports and 79 sedentary recipients (23). In this study, the former group demonstrated significantly higher scores in various domains of the SF-36 scale, including physical function, role limitations due to physical problems, vitality, general health, social functioning, role limitations due to emotional problems, mental health, and social functioning compared to the latter group.

In their study, including 40 KT recipients and comparing the patients in the Pilates group with those in the control group, regarding QoL 1 day before, 3 days, and 3 weeks after KT, Waked et al. reported that the Pilates group had significantly higher scores than the control group 3 weeks after KT (14).

Painter et al. initiated exercise training 1 month after KT and reported that these patients significantly improved concerning the physical function domain of the SF-36 scale one year after KT (19). However, they also noted that exercising only slightly impacted the body composition of their patients. Notably, these authors found a significant association between maximum oxygen consumption level and the physical function of KT recipients.

It is known that the social functioning domain of the SF-36 can be affected by the social and physical isolation process experienced after KT. Due to the risk of COVID-19 and the necessity for immunosuppressive use, participants tended to avoid crowded environments post-KT.

In their study conducted with patients who had previously undergone KT, Lima et al. stated that a combined exercise program consisting of aerobic and strengthening exercises for 12 weeks was associated with lower serum urea and creatinine levels, along with increases in GFR and oxygen consumption in the exercise group while the control group had higher serum urea and creatinine levels and a lower GFR (18). This finding indicated that combined exercise training positively affected graft function in KT recipients.

#### Conclusion

The early post-KT period is of utmost importance for the recipients, and incorporating respiratory physiotherapy into the standard patient management protocols can enhance recipients' physical activity levels while reducing mortality and morbidity. We suggest that respiratory physiotherapy be given to all KT recipients, starting from the preoperative period.

# **Conflicts of interest**

The authors have no conflicts of interest to declare.

## Funding

This study was unfunded.

#### **Ethical approval**

The study received approval from the Akdeniz University Clinical Research Ethics Committee (KAEK-279/ 08.04.2020).

## References

- 1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. *Lancet* 2017;389(10075):1238-1252.
- Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. *Lancet* 2018;392(10159):2052-2090.
- Menjivar A, Torres X, Manyalich M, et al. Psychosocial risk factors for impaired healthrelated quality of life in living kidney donors: results from the ELIPSY prospective study. *Sci Rep* 2020;10(1):21343.
- van den Ham EC, Kooman JP, et al. Similarities in skeletal muscle strength and exercise capacity between renal transplant and hemodialysis patients. *Am J Transplant* 2005;5(8):1957-1965.
- 5. Pencheva VP, Petrova DS, Genov DK, Georgiev OB. Risk factors for lung diseases after renal transplantation. *J Res Med Sci* 2015;20(12):1127-1132.
- Ucan ES, Sayiner A, Akan H, et al. Bağışıklık sistemi baskılanmış hastalarda pnömoni tanı ve tedavi rehberi. *Türk Nefroloji Diyaliz* ve *Transplantasyon Dergisi/Office Journal* of the *Turkish Nephrology Association* 1998;4:158-172
- Zeyneloğlu P. Respiratory complications after solid-organ transplantation. Exp Clin Transplant 2015;13(2):115-125.

- 8. Fishman JA. Infection in renal transplant recipients. Semin Nephrol 2007;27(4):445-461.
- Balbaloğlu Ö. Training Exercise on Pulmonary Rehabilitation. Bozok Tıp Dergisi 2016;6(1):55-59.
- 10. Karacay E. Preoperatif ve postoperatif dönemde pulmoner rehabilitasyon. *Güncel Göğüs Hastalıkları Serisi* 2019;7(1):126-135
- Tuncay F. Pulmoner Rehabilitasyon. *Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi* 2021;
   24(2):169-179.
- Gordon EJ, Prohaska TR, Gallant MP, et al. Longitudinal analysis of physical activity, fluid intake, and graft function among kidney transplant recipients. *Transpl Int* 2009;22(10):990-998.
- 13. Baker LA, March DS, Wilkinson TJ, et al. Clinical practice guideline exercise and lifestyle in chronic kidney disease. *BMC Nephrol* 2022;23(1):75.
- 14. Waked IS, Osman EM, Deghidi AHN. Efficacy of pilates exercises in improving pulmonary functions and quality of life after renal transplantation: A randomized controlled tria. *Int J Health Sci Res* 2016; 6(1):246-253.
- 15. Onofre T, Fiore Junior JF, Amorim CF, Minamoto ST, Paisani DM, Chiavegato LD. Impact of an early physiotherapy program after kidney transplant during hospital stay: a randomized controlled trial. *J Bras Nefrol* 2017;39(4):424-432.
- Grams ST, Ono LM, Noronha MA, Schivinski CI, Paulin E. Breathing exercises in upper abdominal surgery: a systematic review and meta-analysis. *Rev Bras Fisioter* 2012;16(5):345-353.
- 17. Wang DW, Sills LL, MacDonald SB, Maianski Z, Alwayn I. Active video gaming in patients with renal transplant: a pilot study. *Transplant Res* 2014;3:15.
- 18. Lima PS, de Campos AS, de Faria Neto O, et al. Effects of Combined Resistance Plus Aerobic Training on Body Composition, Muscle Strength, Aerobic Capacity, and Renal Function in Kidney Transplantation Subjects. J Strength Cond Res 2021;35(11):3243-3250.
- 19. Painter PL, Hector L, Ray K, et al. A randomized trial of exercise training after renal transplantation. *Transplantation* 2002;74(1):42-48.

- Habedank D, Kung T, Karhausen T, et al. Exercise capacity and body composition in livingdonor renal transplant recipients over time. *Nephrol Dial Transplant* 2009;24(12):3854-3860.
- Hernández Sánchez S, Carrero JJ, Morales JS, Ruiz JR. Effects of a resistance training program in kidney transplant recipients: A randomized controlled trial. *Scand J Med Sci Sports* 2021;31(2):473-479.
- 22. Oguchi H, Tsujita M, Yazawa M, et al. The efficacy of exercise training in kidney transplant recipients: a meta-analysis and systematic review. *Clin Exp Nephrol* 2019;23(2):275-284.
- Mazzoni D, Cicognani E, Mosconi G, Totti V, Roi GS, Trerotola M, Nanni Costa A. Sport activity and health-related quality of life after kidney transplantation. *Transplant Proc* 2014;46(7):2231-2234.



**Case Report** 

## Post-cardiac Catheterization Infective Endocarditis with Flail Mitral Valve Leaflets: A Rare Case

Mohamud Mire Waberi<sup>1</sup>, Mohamed Omar Hassan<sup>1</sup>, Abdijalil Abdullahi Ali<sup>2</sup>, Ishak Ahmed Abdi<sup>1</sup>, Ahmed Elmi Abdi<sup>1</sup>, Said Abdirahman Ahmed<sup>1</sup>

<sup>1</sup>Department of Cardiology, Mogadishu Somali Turkish Training and Research Hospital, Mogadishu, Somalia. <sup>2</sup>Department of Cardiovascular Surgery, Mogadishu Somali Turkish Training and Research Hospital, Mogadishu, Somalia.

| <b>Corresponding Author</b> | Mohamud Mire Waberi               | Email: xusen7777@hotmail.com |
|-----------------------------|-----------------------------------|------------------------------|
| Received                    | August 10 <sup>th</sup> , 2023    |                              |
| Accepted                    | September 30 <sup>th</sup> , 2023 |                              |

AbstractInfectious endocarditis (IE) occurs after colonizing the cardiac endocardium by virulent microorganisms, usually<br/>bacteria. Infective endocarditis causes significant morbidity and mortality, even in this era of antibiotics. Here, we<br/>present a 52-year-old male patient with hypertension and ischemic heart disease who presented with shivering,<br/>fever, and confusion for two days, fourteen days after percutaneous coronary intervention (PCI). On further<br/>assessment, transesophageal echocardiography was done due to the patient's fulfillment of 3 minor and 1 major<br/>of Duke's criteria. The transesophageal echocardiography observed a flail posterior mitral valve leaflet of<br/>1.1x0.60cm vegetation and severe eccentric mitral regurgitation.<br/>Post-PCI infective endocarditis is a rare and missed diagnosis, so it should be a high suspension for those present<br/>with signs and symptoms compatible with infective endocarditis.KeywordsPercutaneous coronary intervention; Infective endocarditis; Vegetation; Echocardiography; Mitral regurgitation

## Introduction

Infective endocarditis (IE) is a rare and life-threatening infection of the endocardium (inner lining of the heart). In decreasing order, the most commonly affected valves are the mitral, aortic, combined mitral-and-aortic, tricuspid, and pulmonic valves (1). In the past 30 years, IE incidence and mortality have risen, especially in areas with higher socio-demographic index (SDI) regions (2). Staphylococcus aureus is the most frequent cause in high-income countries, accounting for up to 40% of cases due to epidemiological reasons (3). There has been a considerable change in the

epidemiology and clinical characteristics of IE during the past ten years. Post-surgical and interventional IE incidence increased significantly (4). The most frequent complication of endocarditis is ischemic stroke. About 20% with infective endocarditis develop ischemic stroke. Patients with commitment cardiomyopathy have a higher risk of AIS (5, 17).

We present a rare case of infective endocarditis with a flail mitral valve leaflet with post-cardiac catheterization.

#### **Case presentation**

A 52-year-old man with hypertension and ischemic heart disease complains of exertional chest pain, shortness of breath (SOB), and fatigue. The vitals were normal. Basic laboratory tests of complete blood count, thyroid, liver, and renal function tests were normal, while electrocardiography showed lateral ST depression of v6 and v7, otherwise normal sinus rhythm. An echocardiogram demonstrated mild mitral regurgitation (MR) with apical hypokinesia. Diagnostic angiography was performed due to unstable angina with 40% diagonal bifurcation, 99% circumflex (CX), and plaque in the right coronary artery (RCA). The circumflex (CX) was opened with 2.5x15mm DES at 12 atm and post-dilated with a 2.5x20 NC balloon (Figure 1). The patient was monitored at the coronary care unit for 24 hours before being discharged on day 2 with the following medications: aspirin 100mg, clopidogrel 75mg, atorvastatin 40mg, metoprolol 25mg BID, and ramipril 2.5mg twice a day.

Fourteen days later, the patient was taken back to the hospital because he had shivering, a fever, and was disorientated for two days. On systemic review, he was confused but otherwise normal, while he has S3 on auscultation of his cardiopulmonary. On abdominal examination, he had mild left upper quadrant pain. Basic laboratory test results were normal, except elevated white blood cell count (15.39x1000/mm3), neutrophil (13.51x1000/mm3), C-reactive protein (65 mg/l),

creatinine (2.61 mg/dL), and urea (130 mg/dL). The chest X-ray revealed vascular congestion compatible with pulmonary edema. Abdominal ultrasound revealed splenic microinfarct.



**Figure 1.** Coronary angiography **a.** RCA with plaque (red arrow), 90% CX (yellow arrow) and occluded 40% diagonal (black arrow). **b.** Wiring of CX (red arrow), at Ballooning (yellow arrow), and final image (black arrow) On the third day of his readmission, the patient developed a decreased level of consciousness and right hemiparesis. Non-contrast brain MRI showed multiple cortical embolic infracts of the brain (Figure 2).

For further investigation of the source of infection, transthoracic echocardiography showed 1.1x0.60cm vegetation of the mitral valve with severe eccentric mitral regurgitation and a dilated left atrium (43mm). In addition, transesophageal echocardiography demonstrated a flail posterior mitral valve, 1.1x0.60cm vegetation, and severe mitral regurgitation (Figure 3).

While waiting for the blood culture, vancomycin and gentamycin were started as empirical therapy based on hospital policy. On day one of blood cultures and seven days later, the results were all

negative. Because our hospital lacks valvular surgery capacity, the patient was referred to a cardiovascular surgeon.



Figure 2. Brain MRI showed multiple cortical embolic infract of the brain (red arrow)



**Figure 3:** A: tans-thoracic echo with mass (1.1x0.60cm) near anterior mitral valve (red circle), flail posterior leaflet, and severe eccentric mitral regurgitation (red arrow). B: transesophageal echocardiography demonstrated flail mitral valve (red arrow), severe mitral regurgitation (green arrow), and vegetation (yellow arrow). **Discussion** 

A bacterial infection of the endocardium known as infectious endocarditis is usually brought on by colonization of streptococci or staphylococci. Fever (90%) and heart murmurs (81%) are the most common presenting symptoms of infectious endocarditis, followed by dyspnea (42.9%) (5). The growing incidence of congenital heart disease, the need for frequent medical care for other co-morbidities, hemodialysis, immunosuppression, and the use of intravenous drugs are all current risk factors for endocarditis (6). After cardiac catheterization and percutaneous coronary artery angioplasty, septic complications are pretty rare (7). In a prospective study, only 0.4% of 960 patients who underwent cardiac catheterization generated positive blood cultures significantly correlated with cardiac catheterizations and percutaneous coronary interventions (8). In our case, although we have adapted the sterilization system of our hospital, he has no risk factor for anything other than cardiac catheterization. According to the infectious endocarditis guidelines, antibiotic prophylaxis is not recommended prior to performing cardiac catheterization, even in high-risk patients (9). Infective endocarditis has many complications, including renal and neurological complications, perivalvular abscess, metastatic infection, septic embolization, and mycotic aneurysms. Acute, sub-acute, or chronic mitral regurgitation can cause mitral leaflet Flail, a rare IE complication, and about 50% of these patients with acute MLF experience sudden onset dyspnea (10). This case presented with acute dyspnea due to a flail posterior mitral valve leaflet with septic embolization of the brain and spleen.

Although infective endocarditis (IE) is rare, it still has high morbidity and mortality. In 267 individuals with definite or possible IE, sepsis (n = 23, 46%), multi-organ failure (n = 8, 16%), heart failure (n = 4, 16%), and sudden death (n = 4) were the primary causes of mortality (11).

Although transthoracic echocardiography is an excellent tool for diagnosing infective endocarditis, about 50% of clinical suspicion of endocarditis is high (12), but it still has a downside. Factors that may increase the downside of TTE include the absence of Staphylococcal bacteremia and fungemia, as well as cultures of negative etiologies (13).

According to the modified European Society of Cardiology Duke criteria, transesophageal echocardiography (TEE) performed better than CT for the detection of valvular IE-related lesions and similarly to CT for the detection of paravalvular IE-related lesions in patients with a confirmed diagnosis of left-side IE (14). Based on his Duke criteria, he had 3 minor and 1 major: echocardiography findings, fiver, glomerulonephritis, and embolic infarct of brain and spleen. Diffusion-weighted MRI (DWI) should be done for all patients with infective endocarditis who develop neurological deficits. The DWI is more sensitive to detect acute ischemic stroke than CT and may show tiny infarcts in cortical, deep cerebral structures and the posterior fossa (15, 16). In this case, DWI showed multiple diffusion restrictions in both cerebral hemispheres, consistent with acute infarct.

Early surgical treatment, especially in high-risk patients, decreases mortality in patients with insufficient antibiotics to eliminate bacterial infection. However, many types of vegetation observed on TEE may still be missed by modern harmonic TTE (15,17).

#### Conclusion

Early suspicion of infective endocarditis should be considered for patients with fever after PCI. Therefore, transthoracic echocardiography should be performed on all patients with suspected infective endocarditis, and most of these patients should also have a TEE assessment.

# Informed consent

Written informed consent was obtained from the patient for publishing the included data.

## References

- Meidrops K, Burkhardt FJ, Osipovs JD, Petrosina E, Groma V, Stradins P. Etiology, Risk Factors and Clinical Outcomes in Infective Endocarditis Patients Requiring Cardiac Surgery. *J Clin Med* 2022;11:1957.
- Yang X, Chen H, Zhang D, Shen L, An G, Zhao S. Global magnitude and temporal trend of infective endocarditis, 1990–2019: results from the Global Burden of Disease Study. *Eur J Prev Card* 2022;29:1277-1286.
- 3. Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: a review. *JAMA* 2018;320:72-83.
- 4. Wang P, Lu J, Wang H, et al. Clinical characteristics of infective endocarditis: analysis of 368 cases. *Zhonghua xin xue Guan Bing za zhi* 2014; 42:140-144.
- Ahmed SA, Karataş M, Öcal L, et al. Isolated left ventricular non-compaction cardiomyopathy complicated by acute ischemic stroke: A rare case report. *Annals Med Surg* 2022; 81:104543.
- 6. Ba DM, Mboup MC, Zeba N, et al. Infective endocarditis in Principal Hospital of Dakar: a retrospective study of 42 cases over 10 years. *Pan Afr Med J* 2017;26.
- Mostaghim AS, Lo HY, Khardori N. A retrospective epidemiologic study to define risk factors, microbiology, and clinical outcomes of infective endocarditis in a large tertiary-care teaching hospital. SAGE Open Med 2017;5:2050312117741772.
- McCready RA, Siderys H, Pittman JN, et al. Septic complications after cardiac catheterization and percutaneous transluminal coronary angioplasty. *J Vasc Surg* 1991;14:170-174.
- 9. Banai S, Selitser V, Keren A, et al. Prospective study of bacteremia after cardiac catheterization. *Am J Cardiol* 2003;92:1004-1007.
- 10. Jayasuriya S, Movahed MR. Infectious endocarditis with systemic septic embolization as a rare complication of cardiac catheterization. *Exp Clin Cardiol* 2009;14: e17.

- Ahmed R, Moaddab A, Graham-Hill S. Mitral Leaflet Flail as a Late Complication of Infective Endocarditis: A Case Report. *Cureus* 2022;14(6):e25854.
- 12. Chu VH, Cabell CH, Benjamin Jr DK, et al. Early predictors of in-hospital death in infective endocarditis. *Circulation* 2004;109(14):1745-1749.
- Evangelista A, Gonzalez-Alujas MT. Echocardiography in infective endocarditis. *Heart* 2004;90:614-617.
- 14. Kini V, Logani S, Ky B, et al. Transthoracic and transesophageal echocardiography for the indication of suspected infective endocarditis: vegetations, blood cultures and imaging. J Am Soc Echocardiogr 2010;23:396-402.
- 15. Sifaoui I, Oliver L, Tacher V, et al. Diagnostic performance of transesophageal echocardiography and cardiac computed tomography in infective endocarditis. *J Am Soc Echocardiogr* 2020;33:1442-1453.
- Abdi IA, Karataş M, Abdi AE, Hassan MS, Mohamud MF. Simultaneous acute cardiocerebral infarction associated with isolated left ventricle non-compaction cardiomyopathy. *Annals Med Surg* 2022;80:104172.
- 17. Hassan MS, Sidow NO, Adam BA, Adani AA. Superior alternating hemiplegia (Weber's syndrome)-Case report. *Annals Med Surg* 2022;77:103674.